Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
120
resultados
Última actualización
27/12/2025 [07:05:00]
Resumen de: AU2024266327A1
The invention relates, inter alia, to methods of preparing a garlic oil, garlic oils produced using the method, pharmaceutical compositions comprising the garlic oil and uses of the garlic oil in the treatment of viral infections such as SARS-COV-2 and influenza A. The methods of preparing a garlic oil comprise the steps of: a) processing a portion of a garlic plant to increase its surface area; b) ageing the portion of the garlic plant for at least 18 months to provide an aged garlic, which does not comprise addition of ethanol; and c) separating the garlic oil in the aged garlic. Step c) may be performed using spinning cone distillation or supercritical fluid extraction, at a temperature below 110 °C, or such that the pressure (atmospheres) divided by the temperature (degrees Kelvin) is equal to or less than about 0.0026.
Resumen de: WO2025257397A1
The inventors have investigated the use of an attenuated B. pertussis strain as a live vehicle for the expression of heterologous antigens (e. g. SARS-CoV-2 N-protein) through the auto-transporter SphB1 secretion machinery. The passenger domain of Sph1 was replaced by N- protein in an expression cassette containing the pertactin signal peptide coding region and promoter region. The chimeric protein was successfully produced and secreted to the extracellular medium. Nasal administration of the live recombinant strains triggered a specific systemic cell-mediated response against N-protein. These results support the use of live attenuated B. pertussis strains as a potential vaccine platform for heterologous antigen delivery.
Resumen de: US2025383359A1
Methods and compositions are disclosed for inducing immunity against a virus such as a coronavirus in the mucosal tissue of a patient, include administering a vaccine composition to the patient by oral administration (e.g., nasal injection, nasal inhalation, oral inhalation, and/or oral ingestion). Compositions for assaying the presence of anti-viral antibodies induced by the administered vaccine or the presence of viral proteins in a saliva sample include an assay protocol for detecting neutralizing antibodies (e.g., IgA) against the virus in the saliva sample. Compositions include a kit including a stabilizing solution for the patient sample (e.g., saliva sample) and may also include conjugated aragonite particle beads for antibody or viral protein capture.
Resumen de: US2025382353A1
The present invention includes monoclonal antibody or antigen-binding fragment thereof, methods of using, detection, recombinant vectors, host cells, kits, variants, and pharmaceutical compositions that include the antibody or antigen-binding fragment thereof that is cross-reactive and binds to different variants of a Spike protein of SARS-CoV-2 (SARS2-S).
Resumen de: US2025381265A1
Provided herein are mutant coronavirus spike proteins, methods of making and using, vaccines, vectors and nucleic acids, comprising at least one of the following modifications: a short flexible peptide linker or a rigid peptide linker in place of the furin cleavage site loop to genetically link an S1 and S2 subunit; at least one additional disulfide bond; or 1, 2, 3, 4, or 5 proline mutations for greater trimeric stability, wherein the mutant coronavirus spike protein has: a higher stability or a higher level of expression when compared to a non-modified coronavirus spike protein. Coronavirus is SARS, MERS, 229E (alpha), NL63 (alpha), OC43 (beta), HKU1 (beta), SARS-CoV-2, or an emerging variant thereof. Cunent SARS-CoV-2 variants include, e.g., B.1.1.7, B.1.1.7 with E484K, B.1.135, B.1.351, P.1, B.1.427, D614G, B.1.1351, or B.1.429, Lambda (i.e., C.37), Mu (i.e., B.1.621), Omicron (B.1.1.529) or a variant (including but not limited to BA.1, BA.2, or BA.3) thereof, and others.
Resumen de: US2025380705A1
Doubly reentrant topology (DRT) is a unique structure. The present invention first validated the outstanding performance of an anti-biofouling artificial surface comprising a superhydrophobic surface; thereon a plurality of microstructures and having a doubly re-entrant topology (DRT) situated atop respective base structures which demonstrates a striking anti-biofouling effect that can prevent viral contamination. Furthermore, the present invention per se features excellent anti-biofouling ability, which may shed light on the applications of pathogen elimination in alleviating the COVID-19 pandemic.
Resumen de: US2025381207A1
Compositions that contain flavonoids such as hesperidin, quercetin, hesperetin, and rutin and methods of treating viral diseases such as coronavirus (e.g., SARS COV-2) infection, influenza virus infection, rhinovirus infection, and human metapneumovirus infection.
Resumen de: WO2025255901A1
A use of a S protein or P4HB protein as a target in preparation of a drug for prevention or treatment of coagulopathy associated with SARS-CoV-2 infection. The S protein is the spike protein of SARS-CoV-2 virus, and the P4HB protein is human protein disulfide isomerase. By means of integrated proteomic and bioinformatic study on SARS-CoV-2 interaction networks in endothelial cells, pulmonary cells, and bronchial cells, the S protein is determined as a key contributor to the procoagulant characteristics of viruses, and the S protein plays a critical role in inducing endothelial cell dysfunction. The S protein directly interacts with P4HB by means of an RBM region thereof, and promotes the secretion of P4HB by means of a lysosomal secretion pathway, thereby promoting thrombosis both in vitro and in a mouse model. Genetic or pharmacological targeting of S-P4HB axis can alleviate coagulopathy in a mouse model. The level of P4HB and disulfide bonds of target proteins thereof are significantly altered in the plasma and leukocytes of COVID-19 patients and are closely associated with the disease severity and coagulation correlation of these patients.
Resumen de: ZA202210474B
The disclosure is directed to methods of using dantrolene or a dantrolene prodrug, or a pharmaceutically acceptable salt thereof, to treat COVID-19 and SARS-CoV-2 infections.
Resumen de: ZA202309169B
Methods and devices for capturing and analyzing aerosolized particles in exhaled breath characteristic of a respiratory disease to enable rapid, low-cost point of care assays for several diseases including respiratory tract diseases such as COVID-19 are disclosed. The disclosed methods and systems selectively capture aerosolized particles using a packed bed column. The captured particles are then eluted using solvents and analyzed using analytical devices including MALDI-TOFMS.
Resumen de: AU2024263334A1
Disclosed herein are coronavirus (CoV) Spike (S) polypeptides, including naturally and non-naturally occurring polypeptides, and nanoparticles and immunogenic compositions comprising the same, which are useful for stimulating immune responses against various SARS-CoV-2 strains. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
Resumen de: WO2025253129A1
This application relates to novel compounds and their use as SARS-CoV-2 Main Protease (Mpro) inhibitors. Compounds described herein may be useful in the treatment of SARS-CoV-2 and related viruses and disorders associated with SARS-CoV-2: Mpro. The application is also directed to pharmaceutical compositions comprising these compounds and the manufacture and use of these compounds and compositions in the treatment of SARS-CoV-2 and related viruses and disorders associated with SARS-CoV-2: Mpro. The compounds and compositions may be useful in preventing death or complications arising due to chronic underlying conditions or comorbidities in patients infected with SARS-CoV-2 and related viruses.
Resumen de: US2025375515A1
A recombinant vaccine is described, which comprises an active Newcastle disease viral vector (NDV) having inserted an exogenous nucleotide sequence of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2), without adjuvant, capable of generating a significant cellular response in T cells (CD4+ or CD8+) when stimulated with the S protein of the SARS-CoV-2 virus or proteins derived from it in individuals with previous immunity.
Resumen de: US2025375416A1
The present invention relates generally to a method of detecting inhibitory effects of health supplements on serine protease in cell lines derived from human carcinomas. More, particularly, the present invention relates to inhibitory analysis of health supplementary products taken from market and/or chemically purified forms, in order to determine their competitors and/or inhibitory effects on serine protease such as trypsin so that these supplements can be used for the treatment once someone develop intense inflammatory reactions either due to infections like COVID-19 and/or pathological conditions such as cancer. The present invention further provides therapeutic applications for agents and/or condition which utilize human enzymatic system and/or cellular components for the development of pathological conditions.
Resumen de: US2025376464A1
The present invention is generally directed to inhibitors of SARS-CoV-2-related 3C-like protease (Mpro) useful in the treatment of coronavirus infection and having the Formula (A):
Resumen de: US2025376490A1
The present disclosure relates to a composition for preventing or treating coronavirus infection, including a hotspot-derived peptide-nucleic acid hybrid molecule. It was confirmed that in vitro evolution-based hotspot-derived peptide-nucleic acid hybrid molecule prepared using the method of the present invention has high binding affinity for the RBDs of SARS-COV-2 VOCs (alpha, beta, gamma, delta, and omicron). In particular, it was found that the greatest binding tolerance was exhibited in the most highly mutated omicron. Furthermore, the hybrid molecule showed high RBD binding affinity in competition with RBD-binding nucleic acid aptamers, macrocyclic peptides, and monoclonal antibodies. The hybrid molecule also exhibited excellent nuclease resistance and serum stability, indicating potential as virus neutralizer in addition to SARS-COV-2.
Resumen de: WO2025255479A1
Methods and compositions for the treatment of viral infections, such as SARS-CoV-2 infection, are disclosed herein which restore mitochondrial function, thereby inhibiting viral propagation.
Resumen de: WO2022135752A1
The present invention refers to the in vitro use of a Coronavirus antigen, measured in plasma, serum or blood samples obtained from the patient, for the prognosis and/or for predicting the mortality risk of patients suffering from Coronavirus infection, for predicting the response of patients suffering from Coronavirus infection to an antiviral therapy or for selecting patients suffering from Coronavirus infection for receiving an antiviral therapy.
Resumen de: US2025368755A1
Disclosed are a peptide specifically binding to a PPC region of a SARS-CoV-2 spike protein and a composition for preventing SARS-CoV-2 infection using the same. The peptide includes a peptide sequence of DGRARQSQDDD or GSQIALRRRDE.
Resumen de: KR20250170783A
본 문서에 설명된 시스템과 방법은 위양성 및 위음성 결과를 최소화하고 새로운 변종을 설명하는 COVID-19 진단 검사 방법에 관한 것입니다. 이 시스템과 방법은 보고된 모든 COVID-19 바이러스 균주를 100% 포괄하는 동시에 탐지 알고리즘을 사용하는 프라이머와 프로브의 조합을 개발하는 데 관한 것입니다.
Resumen de: LU601924B1
A bear bile Chinese medicinal wine for health preservation and disease treatment, which is made of bear bile powder, red dates, wolfberries and white wine, throughout the whole formula of the invention, the compatibility is reasonable, and the effects of clearing heat, calming the liver, invigorating the spleen and stomach, nourishing the kidney and liver, etc. can be achieved, it can not only sterilize and reduce inflammation, but also improve human immunity and prevent virus invasion; it can be not only used externally for traumatic injuries (mechanical injuries and burns), skin diseases, sinusitis, fever, dizziness and other symptoms, but also taken internally for critical nasopharyngitis, excessive internal heat, diseases caused by viral infections (such as sore throat caused by COVID-19), cough, cold, toothache, oral diseases (including periodontitis, halitosis, oral ulcer) and so on.
Resumen de: WO2025246679A1
Provided are a broad-spectrum coronavirus-neutralizing antibody and a use thereof. The antibody CYFN1006-1 comprises a heavy chain variable region VH and a light chain variable region VL, wherein the VH comprises CDRH1 to CDRH3 having amino acid sequences as shown in SEQ ID NOs: 1-3; and the VL comprises CDRL1 to CDRL3 having amino acid sequences as shown in SEQ ID NOs: 4-6. CYFN1006-1 is a broad-spectrum highly-efficient coronavirus-neutralizing antibody, can efficiently neutralize all currently circulating SARS-CoV-2 variants, shows medium efficacy on SARS-CoV, and provides a new choice for solving the problems of viral escape and drug resistance encountered in the application of monoclonal antibody passive immunotherapy against novel coronavirus infection.
Resumen de: WO2025250893A1
Provided herein are methods of analyzing antibody binding. In some embodiments, the methods comprise contacting a set of SARS-CoV-2 protein variant functionalized nanoparticles (MNPs) with a set of antibodies, and contacting a set of ACE2 protein functionalized nanoparticles (MNPs) with the set of antibodies and a set of competition probes that comprise the SARS-CoV-2 protein variant. In some embodiments, the methods also include detecting binding, if any, of the SARS-CoV-2 protein variant functionalized MNPs with the set of antibodies and binding, if any, of the ACE2 protein functionalized MNPs with the set of antibodies and the set of competition probes that comprise the SARS-CoV-2 protein variant. Related systems and kits are also provided.
Resumen de: US2025368689A1
Embodiments provided here include engineered viral proteins, such as but not limited to coronavirus spike proteins, e.g., SARS-CoV-2 spike proteins. These engineered viral proteins comprise modifications or mutations that facilitate secretion and efficient production. Exemplary engineered coronavirus spike proteins of the disclosure can combine mutations in regions of the spike proteins observed in various viruses of concern that have circulated in humans in one singular protein sequence. Additional embodiments provide nucleic acid molecules encoding the coronavirus spike proteins of the disclosure, pharmaceutical compositions and host cells comprising the proteins and/or nucleic acid molecules described here, methods and uses thereof for the prophylactic treatment of infection or disease associated with a coronavirus infection, and methods of producing such coronavirus spike proteins, as well as provide neutralizing antibody titers representing SARS-CoV-2 variants of concern, and high throughput, large scale bioreactor operation methods for production of human vaccines based on purified Spike proteins.
Nº publicación: US2025368651A1 04/12/2025
Solicitante:
UNIV OF KANSAS [US]
UNIVERSITY OF KANSAS
Resumen de: US2025368651A1
Disclosed herein are compound of Formula I, Formula II, or Formula III: or a pharmaceutically acceptable salt and/or solvate of any one or more thereof, pharmaceutical compositions including such compounds, and methods of treating disease by administering or contacting a subject with one or more of the above compounds.
BOPI
Sede Electrónica
